Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...

Among patients with heart failure with preserved ejection fraction (HFpEF), lower versus higher ranges of EF signal fundamentally different morphologies and hemodynamic responses, which may have ...

Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...

Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart ...

It's a new age for heart failure (HF) management, with growing appreciation for its "four pillars" of drug therapy, but also, it appears, the waning status of left ventricular ejection fraction (LVEF) ...

A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...

CLEVELAND -- Lower doses of copper chelator trientine hydrochloride (Syprine) appeared safe and potentially promising for heart failure with low ejection fraction in a phase IIa trial, despite a ...

Population-based studies report that the majority of elderly patients with heart failure have a normal ejection fraction (HF-NEF) and a history of hypertension. Left ventricular diastolic dysfunction, ...